A Phase 1, Single Dose PK and Safety Study With NI-03 Followed by a Phase 2, Randomized, Double-Blind, Parallel-Group Dose-Ranging Study to Evaluate the Safety and Efficacy of NI-03 When Compared to Placebo in Subjects With Chronic Pancreatitis

Trial Profile

A Phase 1, Single Dose PK and Safety Study With NI-03 Followed by a Phase 2, Randomized, Double-Blind, Parallel-Group Dose-Ranging Study to Evaluate the Safety and Efficacy of NI-03 When Compared to Placebo in Subjects With Chronic Pancreatitis

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 14 Nov 2017

At a glance

  • Drugs Camostat mesilate (Primary)
  • Indications Pancreatitis
  • Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
  • Sponsors Stason Pharmaceuticals
  • Most Recent Events

    • 07 Nov 2017 Planned End Date changed from 1 May 2018 to 1 Aug 2018.
    • 07 Nov 2017 Planned primary completion date changed from 1 Mar 2018 to 1 Jul 2018.
    • 07 Aug 2017 Planned End Date changed from 1 Feb 2018 to 1 May 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top